

# SCIENTIFIC REPORTS



OPEN

## Publisher Correction: Structural Implications of Mutations Conferring Rifampin Resistance in *Mycobacterium leprae*

Sundeep Chaitanya Vedithi<sup>1,2</sup>, Sony Malhotra<sup>1</sup>, Madhusmita Das<sup>2</sup>, Sheela Daniel<sup>2</sup>, Nanda Kishore<sup>3</sup>, Anuja George<sup>4</sup>, Shantha Arumugam<sup>2</sup>, Lakshmi Rajan<sup>2</sup>, Mannam Ebenezer<sup>2</sup>, David B. Ascher<sup>5</sup>, Eddy Arnold<sup>6</sup> & Tom L. Blundell<sup>1</sup> 

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-018-23423-1>, published online 22 March 2018

This Article contains typographical errors.

In the Results section under subheading ‘Rifampin Binding in *M. leprae* RNAP’,

“As the activity of rifampin relies on its ability to induce a steric clash with the 5′-ribonucleotide, mutations that influence its orientation in the binding pocket might lead to reduction in these steric clashes resulting in rifampin resistance.”

should read:

“As the activity of rifampin relies on its ability to induce a steric clash with the 5′-ribonucleotide, mutations that influence its orientation in the binding pocket might lead to reduction in these steric clashes resulting in rifampin resistance.”

In the Discussion section,

“Lepromatous leprosy (LL) is characterized by high bacillary loads and low *M. leprae* specific cell-mediated immune responses<sup>32</sup> in the host, increasing likelihood of the presence of bacterial persisters post-treatment which may adopt to rifampin by inducing point mutations with the RRDR.”

should read:

“Lepromatous leprosy (LL) is characterized by high bacillary loads and low *M. leprae* specific cell-mediated immune responses<sup>32</sup> in the host, increasing likelihood of the presence of bacterial persisters post-treatment which may adapt to rifampin by inducing point mutations within the RRDR.”

<sup>1</sup>Department of Biochemistry, University of Cambridge, Tennis Court Rd., Cambridge, CB2 1GA, UK. <sup>2</sup>Molecular Biology and Immunology Division, Schieffelin Institute of Health Research & Leprosy Center (SIH R & LC), Karigiri, Vellore, Tamil Nadu, 632106, India. <sup>3</sup>Department of Dermatology, Father Muller Medical College & Hospital, Mangalore, Karnataka, 575 002, India. <sup>4</sup>Department of Dermatology, Trivandrum Medical College, Trivandrum, Kerala, 695011, India. <sup>5</sup>Department of Biochemistry and Molecular Biology, Bio21 Institute, University of Melbourne, Parkville, VIC 3052, Australia. <sup>6</sup>Center for Advanced Biotechnology and Medicine (CABM), and Rutgers University Department of Chemistry and Chemical Biology, 679 Hoes Lane, Piscataway, NJ, 08854, USA. Correspondence and requests for materials should be addressed to S.C.V. (email: [scv26@cam.ac.uk](mailto:scv26@cam.ac.uk)) or T.L.B. (email: [tlb20@cam.ac.uk](mailto:tlb20@cam.ac.uk))



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018